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Abstract
Cancers often overexpress EGF and other growth factors to promote cell replication and migration. Previous work has
not produced targeted drug carriers sensitive to abnormal amounts of growth factors. This work demonstrates that
liposomes bearing EGF receptors covalently crosslinked to p-toluic acid or methyl-PEO4-NHS ester (or, in short, MRBLs)
exhibit an increased rate of release of encapsulated drug compounds when EGF is present in solution. Furthermore, the
modified EGF receptors retain the abilities to form dimers in the presence of EGF and bind specifically to EGF. These
results demonstrate that MRBLs are sensitive to EGF in solution and indicate that MRBL-reconstituted modified EGF
receptors, in the presence of EGF in solution, form dimers which increase MRBL permeability to encapsulated
compounds.
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Introduction
Cell replication is a fundamental process that maintains the
human body in working order. Although this process is closely
regulated under normal conditions, sometimes cells with delete-
rious genetic mutations may evade these checkpoints and replicate
(rather than undergo apoptosis). If these cells and their daughter
cells are not detected by the immune system, they may continue to
replicate and accrue further deleterious mutations, a process that
may, given time, lead to cancer [1]. Cancers often overexpress
growth factors such as EGF to facilitate cell replication and
migration [2].
Cancers that produce abnormal amounts of EGF, known as
epidermal growth factor (EGF)-overexpressing cancers, have,
along with other types of cancers, drawn enormous expense for
treatment [1,3,4,5]. Such treatment generally involves surgery,
radiation therapy, or generalized chemotherapy, or some
combination thereof. All of these treatment methods are attendant
with significant systemic risks and side effects, and repeat
treatments are often necessary [1,6,7]. Research toward develop-
ing better cancer therapies is of critical importance.
A newer approach for treating EGF-overexpressing cancers
involves EGF receptor inhibitors (EGFRIs). Although EGFRIs
represent an improvement over generalized chemotherapy in
terms of efficacy and specificity, they often need to be used along
with another treatment method (such as radiation therapy) and,
further, are still attendant with potentially significant skin, hair,
nail, and mucosal side effects [8,9,10].
The use of a targeted drug carrier (e.g., a liposome) to release
chemotherapeutic drugs specifically in the neighborhood of EGF-
overexpressing tumors has the potential to achieve the treatment
ideality of maximal efficacy and maximal specificity [11]. Existing
targeted drug carriers are generally triggered by factors such as
ultrasound [12,13]. To use these drug carriers in vivo, ultrasound
waves (or other triggering factor) are aimed at tumors’ precise
locations so that drugs are only released from the carriers when
they are at those locations [12,13]. However, particularly for
metastatic tumors, it is not always possible to identify the tumors’
precise locations [1]. Without this information, it is not possible to
achieve targeted drug delivery with these carriers. Hence, an ideal
targeted drug carrier for EGF-overexpressing tumors would be
one sensitive to abnormal amounts of EGF (i.e., an EGF-triggered
carrier).
Here it is demonstrated in vitro that liposomes bearing EGF
receptors crosslinked to p-toluic acid or methyl-PEO4-NHS ester
(or, in short, MRBLs) are sensitive to EGF in solution.
Results
MRBLs are sensitive to EGF
Assessment of in vitro actinomycin D release from MRBLs
demonstrated that the presence of EGF in solution resulted in an
increased rate of actinomycin D release (Figure 1).
EGF can induce dimerization of modified EGF receptors
It was next sought to verify whether EGF could induce
dimerization of the modified EGF receptors. Modified EGF
receptors and unmodified EGF receptors were assessed with and
without the presence of EGF. In the presence of EGF, modified
and unmodified EGF receptors formed dimers; in the absence of
EGF, only receptor monomers were detected (Figure 2).
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To assess whether MRBL-borne modified EGF receptors retain
specificity for EGF, binding of radiolabeled [
125I]EGF to recon-
stituted receptors was assessed with and without pre-incubation of
the MRBLs with an excess of unlabeled EGF. [
125I]EGF binding
was observed only in the absence of unlabeled EGF pre-incubation
(Figure 3).
Modified EGF receptor dimers affect MRBL permeability
to encapsulated drug
To identify the components underlying the EGF sensitivity of
MRBLs, it was noted that modified EGF receptors retain
specificity for EGF; modified EGF receptors form dimers in the
presence of EGF; and MRBLs bearing these receptors exhibit
sensitivity to EGF in solution. These results indicated that, in the
presence of EGF, MRBL-borne modified EGF receptors form
dimers which increase the MRBL permeability to encapsulated
compounds (Figure 4).
Discussion
This work demonstrates that the transmembrane incorporation
of EGF receptors covalently crosslinked to p-toluic acid or methyl-
PEO4-NHS ester in MRBLs makes these MRBLs sensitive to EGF
in solution. Specifically, when drug compounds are encapsulated
in these MRBLs, a higher rate of in vitro drug release from these
MRBLs is observed when EGF is present (versus when EGF is not
present) in solution. EGF receptors modified with the crosslinking
procedure described herein retain the ability to form dimers in the
presence of EGF. In addition, when these modified EGF receptors
are reconstituted in MRBLs, the MRBLs demonstrate the ability
to bind EGF specifically.
The results imply that modified EGF receptors reconstituted in
MRBLs bind to EGF (if present) in the solution and (if EGF is
present in the solution) form dimers which increase MRBL
permeability to encapsulated compounds. Further work may be
performed to elucidate the precise mechanism whereby MRBL-




Covalent crosslinking procedures have been described previ-
ously [14,15]. For the preparation and collection of MRBLs, lipid
film hydration of egg phosphatidylcholine followed by dialysis and
sucrose gradient centrifugation was used. The dimerization
capability of modified EGF receptors was assayed by SDS-PAGE
electrophoresis as described previously [23]. Reconstituted recep-
tor binding specificity was evaluated using radiolabeled [
125I]EGF
as described [16]. For assessment of drug release from MRBLs,
1H
NMR spectroscopy (400 MHz, CDCl3) was used to evaluate the
increase in amount of released drug in a sample over time
[24,25,26].
Modification of receptors
Methyl-PEO4-NHS ester (an NHS-activated polyethylene oxide
compound) (Pierce) was added at a molar ratio of 1:1 to epidermal
growth factor receptor in 50 mMTris-HCl,150 mM NaCl,0.5 mM
EDTA, 0.02% Triton X-100, 2 mM DTT, 50% glycerol, pH 7.5
(Invitrogen), and the solution was thoroughly mixed. Separately,
p-toluic acid (Alfa Aesar) was added at a molar ratio of 1:1 and
crosslinked to (unmodified) EGF receptor in 50 mM Tris-HCl,
150 mM NaCl, 0.5 mM EDTA, 0.02% Triton X-100, 2 mM DTT,
50% glycerol, pH 7.5 by using EDC and NHS (Pierce) [14,15]. The
two separate solutions were mixed to obtain a single modified EGF
receptor solution.
Preparation of liposomes
Egg phosphatidylcholine (98%; Lipoid) was dissolved in
chloroform in a polypropylene tube. Chloroform was evaporated
with a stream of nitrogen, leaving a thin lipid film, which was
redried under a stream of nitrogen to remove residual traces of
Figure 1. EGF in solution increases rate of encapsulated actinomycin D release. Percentage (expressed as fraction released) of
encapsulated actinomycin D released as assessed by
1H NMR spectroscopy. Baseline Ctrl, actinomycin D-encapsulating MRBLs without growth factor
added to solution. Grth Fctr Ctrl, actinomycin D-encapsulating MRBLs with VEGF added to solution. Expt, actinomycin D-encapsulating MRBLs with
EGF added to solution.
doi:10.1371/journal.pone.0007391.g001
EGF-Sensitive MRBLs
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buffered saline (20 mM Tris, 150 mM NaCl, pH 7.4) containing
50 mM octyl-b-glucoside (Pierce) and thoroughly mixed by
vortexing. The solution was dialyzed for 36 h against three
changes of buffer (Tris-buffered saline, 30 mM benzamidine
(Calbiochem), 0.1 mM PMSF (Pierce)) to remove the detergent,
allowing liposomes to form. The resulting turbid solution was
mixed with sucrose to 40% (w/v) and applied at the bottom of a
sucrose gradient (0.5 mL 40% sucrose, 1.5 mL 20% sucrose,
1.5 mL 5% sucrose), then centrifuged at 40,000 g for 3 h to
Figure 2. EGF induces dimerization of modified EGF receptors.
SDS-PAGE analysis of EGFR dimerization. EGFR+EGF Lane, unmodified
EGF receptors with EGF present. EGFR Lane, unmodified EGF receptors
without EGF present. mod. EGFR + EGF Lane, modified EGF receptors
with EGF present. mod. EGFR Lane, modified EGF receptors without EGF
present. EGF Lane, only EGF present (no EGF receptors present).
doi:10.1371/journal.pone.0007391.g002
Figure 3. MRBL-borne modified EGF receptors show binding specificity for EGF. Binding of [
125I]EGF to MRBLs as assessed by liquid
scintillation counting. Ctrl, MRBLs pre-incubated with an excess of unlabeled EGF before incubation with [
125I]EGF. Expt, MRBLs not pre-incubated
with an excess of unlabeled EGF before incubation with [
125I]EGF.
doi:10.1371/journal.pone.0007391.g003
Figure 4. MRBL-borne modified EGF receptor dimers interact
with the MRBL lipid bilayer to increase MRBL permeability
(schematic). Dimerization of MRBL-borne modified EGF receptors. ext.
sol’n, exterior solution. EGFR, modified EGF receptors. int., interior of
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the top of the gradient. Liposomes were freshly prepared for each
experiment [16,17].
Preparation of drug-encapsulating liposomes
Drug-encapsulating liposomes were generated by the addition
of actinomycin D (EMD Biosciences) to the rehydrated lipid-
containing Tris-buffered saline solution prior to vortexing [17].
Preparation of MRBLs
Modified epidermal growth factor receptor-bearing liposomes
(MRBLs) were generated by the addition of modified EGF
receptor in 50 mM Tris-HCl, 150 mM NaCl, 0.5 mM EDTA,
0.02% Triton X-100, 2 mM DTT, 50% glycerol, pH 7.5 to the
rehydrated lipid-containing Tris-buffered saline solution prior to
vortexing [16,18].
Dimerization assays for free modified EGFR
Analysis of modified EGF receptor dimerization capability was
performed using SDS-PAGE with Coomassie blue staining,
exactly as described [21,22,23].
Binding assays for MRBL-borne modified EGFR
Analysis of modified EGF receptor ligand-binding capability
was performed using radiolabeled [
125I]EGF (PerkinElmer),
exactly as described [16].
Drug release assays
In vitro release experiments were carried out at an incubation
temperature of 298 K by phase separating free drug (i.e.,
unencapsulated drug) and drug-encapsulating MRBLs (i.e.,
encapsulated drug) in a sample at various time points and
removing small aliquots from the free drug phase of the sample.
The change in concentration of unencapsulated drug in the
sample over time was determined using
1H NMR spectroscopy
(400 MHz, CDCl3) [24,25,26].
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